USFDA approves Zydus Lifesciences chronic idiopathic constipation drug Prucalopride
Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Prucalopride Tablets, 1 mg and 2 mg (USRLD: Motegrity Tablets, 1 mg and 2 mg).
Prucalopride is prescribed for chronic idiopathic constipation (CIC), a condition where the cause of constipation is unknown. It helps stimulate peristalsis, natural muscle contractions in the colon, to promote more regular bowel movements.
Prucalopride tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad.
Read also: Zydus Lifesciences gets NOC from Health Canada for ZDS-Varenicline tablets
Prucalopride tablets had annual sales of USD 186.8 mn in the United States (IQVIA MAT June 2025).
The group now has 422 approvals and has so far filed 483* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus bags USFDA nod for chronic stable angina drug Diltiazem Hydrochloride
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.